Brimonidine

UK 14 · UK 14,304 · UBC · HMG20 · RPS27A · CS-1362 · UK 14,34 · UK-11957

식별자 및 물리적 특성

CAS No.	59803-98-4
분자식	C11H10BrN5
평균 분자량	292.13 g/mol
단동위원소 질량	291.01196 g/mol
SMILES	Brc1c(NC2=NCCN2)ccc2nccnc12
InChIKey	XYLJNLCSTIOKRM-UHFFFAOYSA-N
PubChem CID	2435
ChEMBL	CHEMBL844
ChEBI	CHEBI:3175
EC No.	620-306-3
DTXSID	DTXSID3045221

화학 및 물리적 성질

XLogP	0.6
극성 표면적	62.2
수소 결합 공여자 수	2
수소 결합 수용자 수	3
회전 가능 결합 수	2
무거운 원자 수	17
형식 전하	0
복잡도	308
LogP(분배 계수)	1.7
용해도	341.54e-01 g/L11.2 [ug/mL] (The mean of the results at pH 7.4)45%(w/v) 수성 2-히드록시프로필-β-시클로덱스트린: <0.8mg/mL
녹는점	207.5207.5 °C
Physical Description	Solid
Dissociation Constants	7.78
끓는 점	432.6±55.0 °C(Predicted)
밀도	1.82±0.1 g/cm3(Predicted)
저장 조건	Keep in dark place,Sealed in dry,2-8°C
pKa(산도 계수)	7.69±0.10(Predicted)
물리적 상태	powder to crystal
색상	Light yellow to Amber to Dark green
생물학적 소스	mouse
용해도	45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: DMSO: >6.5mg/mLethanol: H2O: insoluble
Merck	14,1375
InChI	InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
InChIKey	XYLJNLCSTIOKRM-UHFFFAOYSA-N
SMILES	N1C2C(=C(Br)C(NC3NCCN=3)=CC=2)N=CC=1

화학적 성질

Yellow Solid

안전 및 규제

GHS 분류	DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 44 reports by companies from 5 notifications to the ECHA C&L Inventory.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Hazard Classes and Categories	Acute Tox. 3 (100%)
노출 경로	Minimal systemic absorption occurs after ocular insertion. When the topical gel was applied to adult patients with facial erythema associated with rosacea, the plasma maximum concentration (Cmax) and area under the concentration-time curve (AUC) were 46 &#17762 pg/mL and 417 &#177264 pg.hr/mL, respectively. These values were reached on Day 15 of treatment.
독성 요약	Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The topical gel reduces erythema through direct vasocontriction.
Signs and Symptoms	Oral LD<sub>50</sub> is 50 mg/kg in mice and 100 mg/kg in rats.
Carcinogen Classification	No indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation	◉ Summary of Use during LactationLimited information indicates that maternal use of brimonidine 0.2% ophthalmic drops do not adversely affect their nursing infants. However, some authors and the manufacturer warn of possible CNS depression, apnea, lethargy, bradycardia with brimonidine and recommend against its use during breastfeeding. To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue. The manufacturer of Combigan states that it is not recommended for use during lactation, but there is no evidence for this statement.

용도

개요

Launched in the US for open-angle glaucoma and ocular hypertension, brimonidine is a relatively selective and potent α2a,-adrenergic agonist with low affinity for the imidazoline l1 receptor. Topical application reduces intraocular pressure. This bypasses any central hypotensive effects at the l1 receptor (which can also give rise to a decrease in blood pressure and heart rate) if given systemically, since topical application results in low plasma levels concomitant with rapid systemic elimination. Brimonidine can be prepared in a four-step sequence from 4-nitrophenylenediamine.

용도

a2-Adrenoceptor agonist. Antiglaucoma